GlaxoSmithKline Pharmaceuticals Limited Financial Ratios
GLAXO · Healthcare · Current price ₹2,567.9
P/E ratio
47.1x
P/B ratio
21.2x
ROE
45.7%
ROCE
62.1%
Debt / Equity
0.00
Dividend yield
2.0%
Ratio reference
| Ratio | Value | What it means |
|---|---|---|
| P/E | 47.1x | Price paid per ₹1 of annual earnings — lower is cheaper (context-dependent). |
| P/B | 21.2x | Price relative to book value — <1 can signal deep value or trouble. |
| ROE | 45.7% | Return on equity — how much profit the company earns on shareholder capital. |
| ROCE | 62.1% | Return on capital employed — efficiency including debt. >15% is strong. |
| D/E | 0.00 | Leverage — higher means more debt-funded, riskier in downturns. |
Model it yourself — PEG Ratio Calculator
Opens pre-filled with GlaxoSmithKline Pharmaceuticals Limited's latest numbers.
GlaxoSmithKline Pharmaceuticals Limited profitability
GlaxoSmithKline Pharmaceuticals Limited generates a return on equity of 45.7% and a return on capital employed of 62.1%. An ROE consistently above 15% usually points to a quality business with a durable advantage; below 10% suggests weak profitability or a capital-heavy model.
Leverage & valuation
With a debt-to-equity of 0.00 and a P/E of 47.1x, GlaxoSmithKline Pharmaceuticals Limited is conservatively financed. Our overall business-quality score for the company is 6.4 / 10.
Understand the ratios
More on GlaxoSmithKline Pharmaceuticals Limited
DocStoX estimates are computed from reported financials, for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.